LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $28.80.

LENZ has been the topic of a number of research reports. Weiss Ratings lowered LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 9th. Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a report on Wednesday, August 12th. Piper Sandler dropped their price objective on shares of LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 12th. Zacks Research upgraded shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a report on Tuesday, July 7th.

Institutional Trading of LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at $13,019,000. Blue Owl Capital Holdings LP bought a new stake in LENZ Therapeutics in the second quarter worth approximately $4,298,000. Primecap Management Co. CA acquired a new position in shares of LENZ Therapeutics during the 2nd quarter valued at $2,682,000. Bank of America Corp DE raised its holdings in shares of LENZ Therapeutics by 377.4% during the first quarter. Bank of America Corp DE now owns 547,534 shares of the company’s stock valued at $5,010,000 after purchasing an additional 432,846 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in LENZ Therapeutics by 16.0% in the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company’s stock worth $9,924,000 after acquiring an additional 240,597 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Price Performance

LENZ stock traded down $0.04 during trading on Friday, reaching $4.09. 85,408 shares of the company were exchanged, compared to its average volume of 913,850. The company has a market capitalization of $128.51 million, a price-to-earnings ratio of -1.00 and a beta of 0.66. The company has a 50-day moving average of $5.08 and a two-hundred day moving average of $7.36. LENZ Therapeutics has a twelve month low of $4.01 and a twelve month high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $2.38 million. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 53.39%. On average, analysts forecast that LENZ Therapeutics will post -4.18 EPS for the current year.

About LENZ Therapeutics

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye’s ability to focus on near objects. The company’s lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision.

In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults.